MK-2206
- Generic Name
- MK-2206
- Drug Type
- Small Molecule
- Chemical Formula
- C25H21N5O
- CAS Number
- 1032349-93-1
- Unique Ingredient Identifier
- 51HZG6MP1K
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01169649
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01147211
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2
Recruiting
- Conditions
- HER2-negative Breast CancerHormone Receptor Positive TumorAngiosarcomaTNBC - Triple-Negative Breast CancerBreast NeoplasmsBreast TumorsHER2-positive Breast CancerHormone Receptor Negative TumorBreast CancerEarly-stage Breast Cancer
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: Datopotamab deruxtecan + DurvalumabDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT01021748
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Phase 1
Terminated
- Conditions
- Advanced Solid TumorsBreast Cancer
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00963547
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Phase 1
Completed
- Conditions
- Locally Advanced, Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00848718
Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Phase 1
Completed
- Conditions
- Locally Advanced TumorsMetastatic Solid TumorsNeoplasmsCancer
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 104
- Registration Number
- NCT00670488
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath